Entresto Hurdles Dog Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Entresto's slow market start following its US approval prompted many questions as Novartis AG reported its quarterly results Oct. 27.
You may also be interested in...
Novartis Settlement Encompasses Whistleblower Claims Of Kickbacks For Diovan Prescribing
The company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.